囊性纖維化治療市場機會、成長動力、產業趨勢分析及 2025-2034 年預測

2024 年全球囊性纖維化治療市場價值為 157 億美元，預計 2025 年至 2034 年的複合年成長率為 15.9%。囊性纖維化 (CF) 盛行率的不斷上升以及對有效治療方案的日益關注，對市場成長做出了重大貢獻。 CF 病例數的不斷增加，增加了早期診斷和改善治療方案的需求，從而推動了對創新治療的需求。研發投資加速了潛在療法的進步，特別是 CF 跨膜傳導調節劑 (CFTR) 調節劑，從而擴大了臨床試驗的範圍。這些努力旨在提高治療效果、滿足未滿足的醫療需求、拓寬市場成長機會。

全球市場分為藥物和非藥物類別。 2023 年醫藥領域價值為 119 億美元，預計 2024 年將創造 140 億美元的收入。預計在整個預測期內它將保持主導地位，複合年成長率為 16.1%。此部分包括 CFTR 調節劑、支氣管擴張劑、抗感染劑、黏液溶解劑、胰酶補充劑和其他藥物類別。 CF 藥物治療（尤其是 CFTR 調節劑和其他症狀治療）的持續進步極大地促進了需求。這些藥物透過針對 CF 症狀和基因突變來改善患者的治療效果。不斷增加的研發投入將繼續提高治療的可用性，以鞏固該領域在市場上的地位。個人化醫療的擴展和更廣泛的報銷支持也是推動該領域成長的關鍵因素。

依年齡段，市場分為18歲以下、18-40歲、41歲以上。 2024 年，18 歲以下族群的市佔率最大，為 76.8%。兒童和青少年的 CF 發生率很高，這推動了對早期診斷和針對性治療的需求。大多數病例是在兒童早期發現的，需要及時介入和專門治療。獲得改進的診斷工具和創新療法的機會不斷增加，進一步促進了該領域的成長。兒科研究和監管批准在確保整個預測期內繼續佔據主導地位方面也發揮著至關重要的作用。

2024 年，美國在北美囊性纖維化治療市場中佔有相當大的佔有率，市場規模將從 2023 年的 89 億美元成長至 105 億美元，複合年成長率為 15.9%。該國 CF 患病率高，刺激了對有效治療的需求，並得到了旨在控制疾病負擔的強大研發計劃的支持。來自政府和私營部門的大量資金繼續推動藥物開發的創新，特別是在 CFTR 調節劑和先進療法方面。透過新型藥物配方擴大治療選擇進一步促進了市場成長。強力的報銷政策和領先製藥公司的存在有助於該國在市場上保持領先地位。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

• 產業生態系統分析
• 產業衝擊力
  • 成長動力
    • 囊性纖維化患者發生率不斷上升
    • CFTR調節劑治療的進展
    • 研發投入不斷增加
    • 政府支持和舉措
  • 產業陷阱與挑戰
    • 治療費用高
    • 目前療法的不良副作用
• 成長潛力分析
• 管道分析
• 流行病學情景
• 監管格局
• 未來市場趨勢
• 波特的分析
• PESTEL分析

第4章：競爭格局

• 介紹
• 公司矩陣分析
• 公司市佔率分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 策略儀表板

第5章：市場估計與預測：按類型，2021 年至 2034 年

• 主要趨勢
• 藥物
  • 藥品類別
    • CFTR調節劑
    • 黏液溶解劑
    • 支氣管擴張劑
    • 抗感染藥物
    • 胰酵素補充劑
    • 其他藥物類別
  • 給藥途徑
    • 口服
    • 吸入
  • 配銷通路
    • 醫院藥房
    • 零售藥局
    • 網路藥局
• 非藥物治療

第6章：市場估計與預測：依年齡層，2021 年至 2034 年

• 主要趨勢
• 18歲以下
• 18 - 40歲
• 41歲以上

第7章：市場估計與預測：按地區，2021 年至 2034 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 愛爾蘭
• 亞太地區
  • 印度
  • 日本
  • 澳洲
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第8章：公司簡介

• Alcresta Therapeutics
• Baxter
• Chiesi Farmaceutici SpA
• F. Hoffmann-La Roche
• Gilead
• Koninklijke Philips NV
• Lupin
• Monaghan Medical
• Novartis AG
• Savara
• Sionna Therapeutics
• Teva Pharmaceutical Industries
• Vertex Pharmaceuticals

The Global Cystic Fibrosis Therapeutics Market was valued at USD 15.7 billion in 2024 and is projected to grow at a CAGR of 15.9% from 2025 to 2034. The increasing prevalence of cystic fibrosis (CF) and the rising focus on effective treatment solutions have contributed significantly to market growth. The growing number of CF cases has heightened the need for early diagnosis and improved therapeutic options, driving demand for innovative treatments. Research and development investments have accelerated advancements in potential therapies, particularly CF transmembrane conductance regulator (CFTR) modulators, leading to an expanding pipeline of clinical trials. These efforts aim to enhance treatment effectiveness and address unmet medical needs, broadening growth opportunities in the market.

The global market is segmented into medication and non-medication categories. The medication segment, valued at USD 11.9 billion in 2023, is projected to generate USD 14 billion in revenue in 2024. It is expected to maintain its dominance throughout the forecast period, growing at a CAGR of 16.1%. This segment includes CFTR modulators, bronchodilators, anti-infective agents, mucolytic agents, pancreatic enzyme supplements, and other drug classes. The growing advancements in CF drug therapies, particularly CFTR modulators and other symptomatic treatments, have significantly boosted demand. These medications improve patient outcomes by targeting CF symptoms and genetic mutations. Increasing research and development investments continue to enhance treatment availability, strengthening the segment's position in the market. The expansion of personalized medicine and broader reimbursement support are also key factors fueling segment growth.

Based on age group, the market is divided into Below 18 years, 18-40 years, and 41 years and above. In 2024, the Below 18 years segment held the largest market share at 76.8%. The high occurrence of CF in children and adolescents has driven demand for early diagnosis and targeted therapies. Most cases are identified in early childhood, necessitating prompt intervention and specialized treatments. Growing access to improved diagnostic tools and innovative therapies further reinforces segment growth. Pediatric research and regulatory approvals also play a crucial role in ensuring continued dominance throughout the forecast period.

In 2024, the United States held a significant share of the North American cystic fibrosis therapeutics market, generating USD 10.5 billion, up from USD 8.9 billion in 2023, with a CAGR of 15.9%. The high prevalence of CF in the country has fueled the demand for effective treatments, supported by strong research and development initiatives aimed at managing the disease burden. Extensive funding from both government and private sectors continues to drive innovations in drug development, particularly in CFTR modulators and advanced therapies. Expanding treatment options through novel drug formulations further boosts market growth. Strong reimbursement policies and the presence of leading pharmaceutical companies contribute to the country's sustained leadership in the market.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing incidence rate of cystic fibrosis patient population
    • 3.2.1.2 Advancements in CFTR modulator therapy
    • 3.2.1.3 Growing investment in research and development
    • 3.2.1.4 Government support and initiatives
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High treatment costs
    • 3.2.2.2 Adverse side effects of current therapies
• 3.3 Growth potential analysis
• 3.4 Pipeline analysis
• 3.5 Epidemology scenario
• 3.6 Regulatory landscape
• 3.7 Future market trends
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Medication
  • 5.2.1 Drug class
    • 5.2.1.1 CFTR modulators
    • 5.2.1.2 Mucolytic agents
    • 5.2.1.3 Bronchodilators
    • 5.2.1.4 Anti-infective agents
    • 5.2.1.5 Pancreatic enzyme supplements
    • 5.2.1.6 Other drug classes
  • 5.2.2 Route of administration
    • 5.2.2.1 Oral
    • 5.2.2.2 Inhalation
  • 5.2.3 Distribution channel
    • 5.2.3.1 Hospital pharmacies
    • 5.2.3.2 Retail pharmacies
    • 5.2.3.3 Online pharmacies
• 5.3 Non-medication

Chapter 6 Market Estimates and Forecast, By Age Group, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Below 18 years
• 6.3 18 - 40 years
• 6.4 41 and above

Chapter 7 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 UK
  • 7.3.3 Ireland
• 7.4 Asia Pacific
  • 7.4.1 India
  • 7.4.2 Japan
  • 7.4.3 Australia
• 7.5 Latin America
  • 7.5.1 Brazil
  • 7.5.2 Mexico
  • 7.5.3 Argentina
• 7.6 Middle East and Africa
  • 7.6.1 South Africa
  • 7.6.2 Saudi Arabia
  • 7.6.3 UAE

Chapter 8 Company Profiles

• 8.1 Alcresta Therapeutics
• 8.2 Baxter
• 8.3 Chiesi Farmaceutici S.p.A.
• 8.4 F. Hoffmann-La Roche
• 8.5 Gilead
• 8.6 Koninklijke Philips N.V.
• 8.7 Lupin
• 8.8 Monaghan Medical
• 8.9 Novartis AG
• 8.10 Savara
• 8.11 Sionna Therapeutics
• 8.12 Teva Pharmaceutical Industries
• 8.13 Vertex Pharmaceuticals